Ifosfamin 2g IV Inj. 1`s

A qualified oncology team administers it with mesna and extensive IV hydration to prevent bladder toxicity.

Ifosfamin 2g IV Injection Ingredients and Usage

Ifosfamin 2g IV Injection contains ifosfamide, a nitrogen mustard alkylating agent chemically related to cyclophosphamide. Oncologists prescribe it in combination with other antineoplastic agents for third line chemotherapy of germ cell testicular cancer.

Ifosfamin 2g IV Injection also treats bronchogenic lung cancer, breast cancer, ovarian cancer, and soft tissue sarcomas. It is always given with mesna to protect the bladder and with extensive fluid hydration, under the supervision of an oncologist experienced in chemotherapy administration.

How Does Ifosfamin 2g IV Injection Work?

Ifosfamide is metabolized in the liver into active alkylating compounds that attach to DNA within cancer cells. These compounds form crosslinks between DNA strands, physically preventing the DNA from separating during replication.

By blocking DNA replication, Ifosfamin 2g IV Injection stops cancer cells from dividing and triggers cell death. This alkylating action affects rapidly dividing cells throughout the body, which explains both its anticancer effect and its impact on bone marrow and bladder tissue.

Ifosfamin 2g IV Injection Side Effects

Ifosfamin 2g IV Injection commonly causes blood count changes and bladder related side effects. Mesna co-administration reduces bladder toxicity risk.

• Low white blood cell count and low red blood cell count

• Nausea and vomiting

• Hair loss

• Drowsiness

• Blood in the urine

• Increased risk of infection

• Fatigue

Warnings

• Ifosfamin 2g IV Injection can cause severe myelosuppression that may lead to fatal infections; complete blood counts must be monitored before, during, and after treatment.

• The medicine can cause severe central nervous system toxicity, including confusion, hallucinations, and coma; monitor closely for signs of encephalopathy during and after treatment.

• Nephrotoxicity can be severe and result in kidney failure; kidney function must be monitored throughout treatment.

• Hemorrhagic cystitis, a severe bladder toxicity, can occur; mesna and extensive hydration of at least two liters of fluid per day are required to reduce this risk.

• Ifosfamin 2g IV Injection can cause cardiotoxicity, including arrhythmias and cardiomyopathy, particularly in patients with pre-existing heart conditions or prior treatment with other cardiotoxic drugs.

• Pulmonary toxicity, including interstitial pneumonitis and pulmonary fibrosis, has occurred with fatal outcomes in some cases.

• Avoid use in patients with known hypersensitivity to ifosfamide or urinary outflow obstruction; use with caution in pregnancy, since it can cause fetal growth retardation and neonatal anemia.

Ifosfamin 2g IV Injection Storage Conditions

Store Ifosfamin 2g IV Injection at controlled room temperature between 20°C and 25°C, protected from temperatures above 30°C. Keep the vial in its original packaging until immediately before use. Store this medicine out of reach of children and ensure only trained healthcare staff handle preparation and administration.